Bayer (BAYRY)
(Delayed Data from OTC)
$6.97 USD
+0.02 (0.29%)
Updated Jun 27, 2024 10:25 AM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Bayer Aktiengesellschaft (BAYRY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.60 | $7.60 | $7.60 | 9.35% |
Price Target
Only one analyst offered a short-term price target of $7.60 for Bayer Aktiengesellschaft. This represents an increase of 9.35% from the last closing price of $6.95.
Analyst Price Targets (1 )
Broker Rating
Bayer Aktiengesellschaft currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, one is Strong Buy, representing 7.69% of all recommendations. A month ago, Strong Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 10 | 10 | 10 | 9 | 9 |
Sell | 2 | 2 | 2 | 2 | 2 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/14/2024 | Berenberg Bank | Sebastian Bray | Hold | Hold |
5/30/2024 | Goldman Sachs | James Quigley | Not Available | Hold |
3/7/2024 | Not Identified | Not Identified | Not Available | Hold |
3/5/2024 | Not Identified | Not Identified | Hold | Hold |
2/29/2024 | Not Identified | Not Identified | Not Available | Hold |
1/30/2024 | Not Identified | Not Identified | Strong Buy | Hold |
12/18/2023 | Not Identified | Not Identified | Hold | Moderate Sell |
12/4/2023 | UBS | Michael Leuchten | Not Available | Hold |
11/20/2023 | Exane BNP Paribas | Laurent Favre | Not Available | Strong Buy |
11/20/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 13 |
Average Target Price | $7.60 |
LT Growth Rate | NA |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | 0.25 |